MAZE Maze Therapeutics, Inc.

NEUTRAL Impact: 3/10 Institutional Cluster
Horizon weeks Processed 9d 20h ago
Institutional cluster: 3 buyers, 0 sellers (bullish)
Latest settled — T+5d
MAZE ▲ +3.11% at T+5d
NEUTRAL call ✓ call won +3.11% · α vs SPY +2.68% · entry $24.09 → $24.84
Next anchor: T+20d in 19d
Entry anchored
Jun 10, 03:59 PM ET
via Databento tick
T+1d
-0.17%
call -0.17% · α -0.71%
$24.05
settled 9d ago
T+5d
+3.11%
call +3.11% · α +2.68%
$24.84
settled 3d ago
T+20d
call — · α —
in 19d
T+60d
call — · α —
in 3mo

Executive Summary

Three mega-passive institutional investors (Vanguard, BlackRock, Morgan Stanley) collectively doubled their positions in Maze Therapeutics during Q3 2025, adding $61.2M in new holdings to reach $74.3M total. This is a passive index-driven accumulation signal, not an active fundamental thesis, and follows a period of poor historical stock performance with zero winning calls at T+20.

Key Financial Metrics

Direction
accumulating
Buy Value
$74.3M
Sell Value
$0.00
Net Flow
$61.2M

Institutional Positions

Net institutional flow: $61.2M

▲ Buyers (3)

InstitutionActionChangePosition ValueValue Δ
Vanguard DOUBLED +218.1% $34.6M $29.5M
BlackRock DOUBLED +114.1% $34.1M $26.6M
Morgan Stanley DOUBLED +569.5% $5.5M $5.1M

Actionable Insight

The cluster is entirely passive/index-driven (Vanguard, BlackRock, Morgan Stanley), likely reflecting index rebalancing or ETF inflows rather than a fundamental thesis. With MAZE's historical T+20 performance deeply negative and zero prior winning calls, this passive accumulation does not signal near-term upside. Monitor for active manager 13F filings or insider buying for a more reliable signal.

Key Facts

  • 3 institutional buyers, 0 sellers in Q3 2025
  • Aggregate net buying: $61.2M (from $13.0M to $74.3M)
  • Vanguard doubled shares (+218.1%), BlackRock doubled (+114.1%), Morgan Stanley increased 569.5%
  • All three buyers are mega-passive/index funds — not active managers
  • Historical MAZE reports show 0% win rate at T+20 (n=6 settled), avg T+20 return -13.45%

Financial Impact

3 institutions accumulated $61.2M in new positions, bringing total disclosed holdings to $74.3M

institutional ownershipfloat

Risk Factors

  • Passive buying provides no fundamental validation — may be mechanically reversed in next rebalance
  • Historical MAZE reports show consistent negative T+20 returns regardless of filing type
  • No active manager participation suggests lack of conviction from informed capital

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-MAZE-2025-Q3
8 reports for MAZE
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MAZE — sortable, filterable
Type Now
Jun 11, 2026
9d ago
Institutional Cluster
NEUTRAL ★ 3/10
$24.09 $24.84▲ +3.11%▲ +2.68%
Jun 3, 2026
17d ago
Insider Cluster
BEARISH ★ 4/10
$25.40 $24.09▲ +5.16%▲ +2.60%
May 22, 2026
29d ago
8-K
NEUTRAL ★ 2/10
$26.35 $24.29▼ −7.82%▼ −9.03%
May 18, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$24.46 $26.05▲ +6.50%▲ +4.20%
May 12, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$26.96 $24.46▼ −9.27%▼ −8.12%
May 12, 2026
5w ago
Press Release
MIXED ★ 5/10
$26.96 $24.46▼ −9.27%▼ −8.12%
Apr 22, 2026
8w ago
424B5
NEUTRAL ★ 5/10
$26.01 $25.68▼ −1.27%▼ −2.75%
Mar 25, 2026
12w ago
Press Release
BULLISH ★ 8/10
$31.73 $29.05▼ −8.45%▼ −8.20%
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (29h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access